Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CIP2A Double Nickase Plasmid (h): sc-401363-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CIP2A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CIP2A Double Nickase Plasmid (h) and CIP2A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CIP2A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CIP2A Antibody (HL1925): sc-80662
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CIP2A Double Nickase Plasmid (h) | sc-401363-NIC | 20 µg | $410.00 | |||
CIP2A Double Nickase Plasmid (h2) | sc-401363-NIC-2 | 20 µg | $410.00 |
Human CIP2A (cellular inhibitor of PP2A) encodes an oncoprotein that suppresses PP2A tumor suppressor phosphatase activity, thereby sustaining phosphorylation-dependent signaling outputs. By stabilizing factors such as c-MYC and supporting PI3K/AKT and MAPK pathway flux, CIP2A contributes to cell-cycle progression, survival signaling, and stress response programs. Dysregulated CIP2A expression is frequently associated with proliferative and invasive phenotypes across multiple cancer contexts and is used as a mechanistic node to interrogate phosphatase-controlled signaling networks. CIP2A is therefore widely studied for its impact on oncogenic signal amplification, chromatin-associated transcriptional regulation, and pathway feedback control.
CIP2A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CIP2A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CIP2A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CIP2A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CIP2A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.